The clinical trial investigates the efficacy of Liraglutide, a GLP-1 receptor agonist, in treating coronary microvascular dysfunction in women with angina pectoris but no obstructive coronary artery disease. Given the increasing prevalence of cardiovascular diseases and the lack of effective treatments for microvascular angina, successful outcomes could position Liraglutide as a novel therapeutic option in this niche market. The trial's completion may enhance the commercial viability of Liraglutide beyond its current indications for diabetes and obesity, potentially expanding its market share. However, competition from other GLP-1 receptor agonists and cardiovascular therapies must be considered in market positioning and strategy.